Matthew McCullough - Dominari Holdings General Counsel
| DOMH Stock | 1.57 0.06 3.68% |
Executive
Matthew McCullough is General Counsel of Dominari Holdings
| Age | 38 |
| Address | 725 5th Avenue, New York, NY, United States, 10022 |
| Phone | 212-393-4540 |
| Web | https://www.dominariholdings.com |
Dominari Holdings Management Efficiency
The company has return on total asset (ROA) of (0.1674) % which means that it has lost $0.1674 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4697) %, meaning that it created substantial loss on money invested by shareholders. Dominari Holdings' management efficiency ratios could be used to measure how well Dominari Holdings manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.42. The current Return On Capital Employed is estimated to decrease to -0.41. As of now, Dominari Holdings' Other Current Assets are increasing as compared to previous years. The Dominari Holdings' current Total Current Assets is estimated to increase to about 29.5 M, while Other Assets are projected to decrease to under 1.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
| Mike Rhee | Senti Biosciences | N/A | |
| MD MBA | SAB Biotherapeutics | 51 | |
| Thomas Chung | Senti Biosciences | N/A | |
| Anuj MD | Assembly Biosciences | 46 | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Steven CPA | NextCure | 61 | |
| Kevin Shaw | NextCure | 49 | |
| Sourav Kundu | NextCure | 63 | |
| Michael Alonso | Bolt Biotherapeutics | N/A | |
| Udayan MD | NextCure | N/A | |
| Richard Colonno | Assembly Biosciences | 74 | |
| Robert MBBS | Instil Bio | N/A | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Dee Dragon | Senti Biosciences | N/A | |
| Amy CFA | Assembly Biosciences | N/A | |
| Nathan Ihle | Bolt Biotherapeutics | N/A | |
| Lee Stern | Achilles Therapeutics PLC | N/A | |
| PharmD BCOP | Bolt Biotherapeutics | N/A | |
| Thomas Rollins | Assembly Biosciences | 68 | |
| Tamara LLM | Spero Therapeutics | 62 | |
Management Performance
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.17 |
Dominari Holdings Leadership Team
Elected by the shareholders, the Dominari Holdings' board of directors comprises two types of representatives: Dominari Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dominari. The board's role is to monitor Dominari Holdings' management team and ensure that shareholders' interests are well served. Dominari Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dominari Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anthony Esq, CEO Chairman | ||
| Matthew McCullough, General Counsel | ||
| Jaime Mercado, Chief Officer | ||
| Soo Yu, Director Manager | ||
| Christopher Devall, Chief Officer | ||
| George CPA, Chief Officer | ||
| Kyle Wool, President Director |
Dominari Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dominari Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.80) % | ||||
| Operating Margin | (0.79) % | ||||
| Current Valuation | 5.83 M | ||||
| Shares Outstanding | 6.28 M | ||||
| Shares Owned By Insiders | 35.43 % | ||||
| Shares Owned By Institutions | 7.29 % | ||||
| Number Of Shares Shorted | 11.15 K | ||||
| Price To Book | 0.26 X |
Currently Active Assets on Macroaxis
When determining whether Dominari Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dominari Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dominari Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dominari Holdings Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dominari Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more detail on how to invest in Dominari Stock please use our How to Invest in Dominari Holdings guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dominari Holdings. If investors know Dominari will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dominari Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.86) | Revenue Per Share 2.113 | Quarterly Revenue Growth 3.198 | Return On Assets (0.17) | Return On Equity (0.47) |
The market value of Dominari Holdings is measured differently than its book value, which is the value of Dominari that is recorded on the company's balance sheet. Investors also form their own opinion of Dominari Holdings' value that differs from its market value or its book value, called intrinsic value, which is Dominari Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dominari Holdings' market value can be influenced by many factors that don't directly affect Dominari Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dominari Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dominari Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dominari Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.